Pharmacological and Non-Pharmacological Interventions for Diabetic Neuropathic Pain: Current Evidence and Clinical Applications

Authors

  • Ankita Raikwar
  • Subhranshu Panda
  • Mahesh Kumar Posa
  • Md. Shamsuzzma

DOI:

https://doi.org/10.63682/jns.v14i32S.9898

Keywords:

Diabetic neuropathy, Neuropathic pain, Hypergylcemia, DNP Models

Abstract

Background: Diabetic neuropathic pain (DNP) is a common and debilitating complication of diabetes mellitus, primarily resulting from chronic hyperglycemia, induced peripheral nerve damage. It manifests as burning, stabbing, and electric shock-like sensations. This review aims to explore the underlying mechanisms, current management strategies, and emerging therapeutic interventions for DNP.

Method: An extensive review of existing literature was conducted to summarize the pathophysiology and treatment approaches for DNP. The study integrates findings from pharmacological and non-pharmacological research, focusing on oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired neurotrophic signaling as key pathological contributors.

Results: Pharmacological therapy remains the mainstay for symptom relief. First-line agents such as duloxetine, pregabalin, and gabapentin demonstrate significant efficacy, while topical treatments like capsaicin and lidocaine patches, along with second-line options including tramadol,  tapentadol,  and  alpha-lipoic  acid,  provide  additional  benefit. Non-pharmacological interventions—such as glycemic control, exercise, psychological support, and lifestyle modifications—enhance overall management outcomes. Emerging therapeutic strategies include gene therapy, mesenchymal stem cell (MSC) transplantation, and targeted molecular therapies involving Nav1.7 sodium channel blockers, TRPV1 antagonists, and AT₂R blockers like Olodanrigan. Neuroregenerative approaches using growth factors (NGF, IGF-1, VEGF), along with antioxidant and anti-inflammatory agents (curcumin, resveratrol, N-acetylcysteine), and neuromodulation techniques (spinal cord stimulation, TENS), show promising preclinical and clinical outcomes.

Conclusion: Effective management of diabetic neuropathic pain requires a multidisciplinary and personalized approach, combining pharmacological and non-pharmacological therapies. Integration of conventional treatments with novel regenerative and molecular strategies offers significant promise for addressing both symptom relief and disease modification in DNP.



Downloads

Download data is not yet available.

References

[1] Tesfaye S, et al., Diabetic neuropathies: update on def., diagnosis criteria, estimation of severity, and treatments. Diabetes care. 2010;33(10):2285.

[2] Callaghan BC, et al., Diabetic neuropathy: Clini. Manifestations and current treatments. The lancet NEURO. 20121;11(6):521-34.

[3] Pop-Busui R, et al, Diabetic neuropathy: a position statement by the Ameri. Diab. Asso. Diab. care. 2016 10;40(1):136.

[4] Feldman EL, Nave KA, Jensen TS, Bennett DL. New horizons in diabetic neuropathy: mecha., bioenergetics, and pain. Neuron. 2017 22;93(6):1296-313.

[5] Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical Picture of neuro. pain. Euro. J. Pharmacol. 2001 19;429(1-3):1-1.

[6] Finnerup, N. B., Kuner, R., & Jensen, T. S. Neuro. pain: from mechanisms to treatment. Physiological reviews, 2021101(1), 259-301.

[7] KANDIL A, PERRET D. Classi.of Neuro. Pain. Neuropathic Pain: A Case-Based Approach to Prac. Manage. 2018 20:11.

[8] Scholz J, et al, The IASP classify. of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019 1;160(1):53-9.

[9] Obrosova IG. Diabetic painful and insensate neuro.: pathogenesis and potential treatments. Neurotherapeutics. 2009 1;6(4):638-47.

[10] Brownlee M. Biochem. and molecular cell bio. of diabetic complications. Nature. 2001 13;414(6865):813-20.

[11] Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nature Reviews Neuro. 2011;7(10):573-83.

[12] Schmidt RE., Dorsey DA., Beaudet LN., & Parvin CA. Diabetic auto neuropathy: the role of selective neurodegeneration and implications for diabetic cardiomyopathy. Frontiers in Endocrinology, 2013, 4, 10.

[13] Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con) fusion of pathogenic mechanisms. Pain. 2020 1; 161:S65-86.

[14] Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes care. 2003 1; 26(5):1553-79.

[15] England JD et al, Distal symmetric polyneuropathy: A def. for clini.Research: Report of the AAN, AAEM, and AAPMR. Neurology. 2005; 64(2):199-207.

[16] Lauria, G., et al, Euro. Fed. of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diag. of small fiber neuropathy. Euro. J. Neurology, 2010 17(7), 903–912.

[17] Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J. Pediatrics. 1994 1 ;125(2):177-88.

[18] Saini T, Mazumder PM. Current advancement in the preclinical models used for the assessment of diabetic neuropathy. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024; 397(5):2727-45.

[19] Gao F, Zheng ZM. Animal models of diabetic neuropathic pain. Experimental and Clini. Endocrinology & Diabetes. 2014; 122(02):100-6.

[20] Fisher AS, Lanigan MT, Upton N, Lione LA. Preclini. neuropathic pain assessment; the importance of translatability and bidirectional research. Frontiers in Pharmacol. 2021, 8;11:614990.

[21] Gao F, Zheng ZM. Animal models of diabetic neuropathic pain. Experimental and Clinical Endocrinology & Diabetes. 2014; 122(02):100-6.

[22] Ziegler D., et al, Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes care. 1999 1; 22(8):1296-301.

[23] Onuţu AH. Duloxetine, an antidepressant with analgesic properties–a preliminary analysis. Romanian Journal of Anaesthesia and Intensive Care. 2015; 22(2):123.

[24] Chalon SA, et al Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsycho Pharmacol. 2003; 28(9):1685-93.

[25] Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Current Neuropharmacol. 2014 1; 12(1):44-56.

[26] Alles SR, Cain SM, Snutch TP. Pregabalin as a pain therapeutic: beyond Ca. channels. Frontiers in cellular neuroscience. 2020 15; 14:83.

[27] Onakpoya IJ, et al., Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ open. 2019 1; 9(1):e023600.

[28] Peppin JF, Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: a review. Therapeutic advances in neurological disorders. 2014; 7(1):22-32.

[29] Arora V, Campbell JN, Chung MK. Fight fire with fire: Neurobiology of capsaicin- induced analgesia for chronic pain. Pharmacol. Therapeu. 2021 1; 220:107743.

[30] Chung MK., Campbell JN. Use of capsaicin to treat pain: mechanistic and therapeutic considerations. Pharmaceuticals. 2016 1;9(4):66.

[31] Dhesi M., Maldonado KA., Patel P., Maani CV. Tramadol. InStatPearls 2024 20. Stat Pearls Publishing.

[32] Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clinical pharmacokinetics. 2004; 43(13):879-923.

[33] Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clini. studies. J. Pain Res. 2019 16:1537-51.

[34] Awoleye MO, Adedeji TG. Revisiting the molecular mechani. of Alpha Lipoic Acid (ALA) actions on metabolism. Pharmacological Research-Natural Products. 2024 1;4: 100073.

[35] Nguyen H., Pellegrini MV., Gupta V. Alpha-lipoic acid. InStatPearls 2024 26. StatPearls Publishing.

[36] Rochette L., Ghibu S., Muresan A., Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian J. physiology and pharmacology. 2015; 93(12):1021-7.

[37] Superti F, Russo R. Alpha-lipoic acid: biological mechanisms and health benefits. Antioxi. 2024; 13(10):1228.

[38] Awoleye MO, Adedeji TG. Revisiting the molecular mechanisms of Alpha Lipoic Acid (ALA) actions on metabolic Pharmacol. Research-Natural Products. 2024 1;4:100073.

[39] Moisset X. et al., Pharmacol. and non-pharmacolgy treatments for neuropathic pain: Systematic review and French recommendations. Revue. Neurologique. 2020 1; 176(5):325-52.

[40] Mata M, Chattopadhyay M, Fink DJ. Gene therapy for the treatment of diabetic neuropathy. Current diabetes reports. 2008; 8(6):431-6.

[41] Kessler JA. et al., VM202 Study Group. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clini. Translational Sci. 2021; 14(3):1176-84.

[42] Jang HN, Oh TJ. Pharmacology and nonpharmacol treatments for painful diabetic peripheral neuropathy. Diab. Metabolism J. 2023 6; 47(6):743-56.

[43] Montagnoli TL. et al, Perspectives on Stem Cell Therapy in Diabetic Neuropathic Pain. Neurology International. 2024 30;16(5):933-44.

[44] Sharma S, Rangarajan RV. Role of regenerative therapeutics in diabetic peripheral neuropathy: current advances and future prospects. Euro. J. Medical and Health Sciences. 2024, 6;6(2):1-0.

[45] Han JW, Sin MY, Yoon YS. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes & metabolism journal. 2013 16; 37(2):91.

[46] Méndez-Morales ST, et al, Diabetic neuropathy: molecular approach a treatment opportunity. Vascul. Pharmacol. 2022 1;143:106954.

[47] Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopatho. and treatment. World J. Diabetes. 2015 15;6(3):432.

[48] Zhu J. et al., Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in endocrinology. 2024 9; 14:1265372.

[49] Okdahl T, Brock C. Molecular aspects in the potential of vitamins and supplements for treating diabetic neuropathy. Current Diabetes Reports. 2021;21(9):31.

[50] Yang Y, Zhao B, Wang Y, Lan H, Liu X, Hu Y, Cao P. Diabetic neuropathy: cutting- edge research and future directions. Signal Transduction and Targeted Therapy. 2025 25;10(1):132.

[51] American Diabetes Asso. Introduction: standards of medical care in diabetes—2022. Diabetes care. 2022 1; 45(Supplement_1):S1-2.

[52] Kluding PM et al., The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J. Diabetes and its Complications. 20121; 26(5):424-9.

[53] Roden DM. Pharmacology and toxicol. of Nav1. 5-class 1 anti-arrhythmic drugs. Cardiac electrophysiology clinics. 2014 6; 6(4):695.

[54] Tikhonov DB, Zhorov BS. Mechanism of sodium channel block by local anesthetics, antiarrhythmics, and anticonvulsants. J. Gen Physiol. 2017 3;149(4):465-81.

[55] Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proceedings of the National Acad. of Sci. 1999 6; 96(14):7635-9.

[56] Basso L, Altier C. Transient receptor potential channels in neuropathic pain. Current opinion in pharmacol. 2017 1; 32:9-15.

[57] Rice AS., et al. , EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, in peripheral neuropathic pain: a randomised, double-blind, placebo-controlled phase 2 clinical trial. The Lancet, 2014, 383(9923), 1637–1647.

[58] Apfel SC. Neurotrophic factor therapy—the devil is in the details. Archives of Neurol., 200259(2), 181–184.

[59] Akbar S, et al., Targeting anti-inflammatory pathways to treat diabetes-induced neuropathy by 6-hydroxyflavanone. Nutrients. 2023, 30;15(11):2552.

[60] Naseri R, et al., Polyphenols for diabetes associated neuropathy: Pharmacol. targets and clini. perspective. DARU J. Pharmaceutical Sciences. 2019; 27(2):781-98.

[61] Kbaydet O, Abou-Ela M, Raafat K. Achillea extracts elicit anti-diabetic neuropathic pain by modulating inflammatory cytokines. J. Traditional and Complementary Med. 20251; 15(4):388-403.

[62] Omar N, Ismail CA, Long I. Tannins in the treatment of diabetic neuropathic pain: research progress and future challenges. Frontiers in Pharmacology. 2022, 10; 12:805854.

[63] Suman Kumar S, Deka D, Kandimalla R, Ghosh A, Barge SR, Kashyap B, Bharadwaj S, Talukdar NC. Emerging Natural and Synthetic Compounds in the Management of Diabetic Neuropathy: Targeting Oxidative Stress and Inflammation.

[64] Siniscalco, D., et al. (2011). Stem cells: a novel treatment for pain. International J. Immunopathology and Pharmacol., 24(2 Suppl), 37S–40S.

[65] Ziegler D, et al., Treatment of symptomatic diabetic polyneuropath. with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropath. Diabetes care, 1999, 22(8), pp.1296-1301.

[66] Slangen R, et al., Spinal cord stimulation and pain relief in painful diabetic peripheral neuropath.: a prospective two-center randomized controlled trial. Diabetes care. 20141;37(11):3016-24.

[67] Cheslow L, Snook AE, Waldman SA. Biomarkers for managing neurodegenerative diseases. Biomolecules. 2024 26;14(4):398.

[68] Bai Y., et al. Gut microbiota and diabetic neuropath.: the potential role of dysbiosis and inflammation. Reviews in the Neurosciences, 2019 30(8), 763–771.

[69] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet. 1998 12;352(9131):837-53..

Downloads

Published

2025-11-15

How to Cite

1.
Raikwar A, Panda S, Kumar Posa M, Shamsuzzma M. Pharmacological and Non-Pharmacological Interventions for Diabetic Neuropathic Pain: Current Evidence and Clinical Applications. J Neonatal Surg [Internet]. 2025 Nov. 15 [cited 2026 Apr. 3];14(32S):10358-73. Available from: https://jneonatalsurg.com/index.php/jns/article/view/9898

Issue

Vol. 14 No. 32S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.